keyword
MENU ▼
Read by QxMD icon Read
search

Proton pump inhibitors and cancer

keyword
https://www.readbyqxmd.com/read/29337457/-pharmacovigilance-update
#1
Françoise Livio
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29298870/proton-pump-inhibitors-and-increased-gastric-cancer-risk-time-related-biases
#2
Samy Suissa, Alain Suissa
No abstract text is available yet for this article.
January 3, 2018: Gut
https://www.readbyqxmd.com/read/29273641/long-term-proton-pump-inhibitor-use-is-a-risk-factor-of-gastric-cancer-after-treatment-for-helicobacter-pylori-a-retrospective-cohort-analysis
#3
Ryota Niikura, Yoku Hayakawa, Yoshihiro Hirata, Atsuo Yamada, Mitsuhiro Fujishiro, Kazuhiko Koike
No abstract text is available yet for this article.
December 22, 2017: Gut
https://www.readbyqxmd.com/read/29247066/helicobacter-pylori-eradication-failure-may-have-confounded-the-recent-large-scale-health-database-study-that-showed-proton-pump-inhibitors-increase-gastric-cancer-risk
#4
https://www.readbyqxmd.com/read/29245331/when-omeprazole-met-with-asymptomatic-clostridium-difficile-colonization-in-a-postoperative-colon-cancer-patient-a-case-report
#5
Boyu Li, Huachong Ma, Zhenjun Wang, Lihong Liu
RATIONALE: Clostridium difficile infection (CDI) is a symptomatic infection due to the spore-forming bacterium, C. difficile. Asymptomatic C. difficile colonization is the stage in absence of symptoms, with a prevalence of 1.4% to 21% on hospital admission. Proton-pump inhibitors (PPIs) was implicated as a novel potential contributor to CDI. PPIs injection could make asymptomatic C. difficile colonization progress to C. difficile associated diarrhea (CDAD). PATIENT CONCERNS: A postoperative colon cancer patient, who had been taking omeprazole for 4 years after operation, got asymptomatic C...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29233672/time-latencies-of-helicobacter-pylori-eradication-after-peptic-ulcer-and-risk-of-recurrent-ulcer-ulcer-adverse-events-and-gastric-cancer-a-population-based-cohort-study
#6
Emma Sverdén, Nele Brusselaers, Karl Wahlin, Jesper Lagergren
BACKGROUND: Helicobacter pylori (H pylori) is associated with peptic ulcer disease and gastric cancer. AIM: To test how various lengths of delays in H pylori eradication therapy influence the risk of recurrent peptic ulcer, ulcer adverse events and gastric cancer. METHODS: This population-based nationwide Swedish cohort study included 29,032 patients receiving H pylori eradication therapy after peptic ulcer disease in 2005-2013. Pre-defined time intervals between date of peptic ulcer diagnosis and date of eradication therapy were analysed in relation to study outcomes...
December 9, 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/29216279/emerging-hazard-effects-of-proton-pump-inhibitor-on-the-risk-of-colorectal-cancer-in-low-risk-populations-a-korean-nationwide-prospective-cohort-study
#7
In Cheol Hwang, Jooyoung Chang, Sang Min Park
PURPOSE: Despite plausible mechanisms, the clinical significance of long-term proton pump inhibitor (PPI) use to colorectal cancer (CRC) remains unknown. The purpose of this study was to investigate the association between PPI use and CRC development. METHODS: We conducted a population-based prospective cohort study using the Korean nationwide claims database merged with national health examination data. The study cohort included a total of 451,284 participants who were tracked to identify cases of CRC since 2007...
2017: PloS One
https://www.readbyqxmd.com/read/29199147/factors-associated-with-progression-of-barrett-s-esophagus-a-systematic-review-and-meta-analysis
#8
Rajesh Krishnamoorthi, Siddharth Singh, Karthik Ragunathan, Kavel Visrodia, Kenneth K Wang, David A Katzka, Prasad G Iyer
BACKGROUND & AIMS: Endoscopic surveillance of patients with Barrett's esophagus (BE) is inefficient. Risk stratification of patients might improve the effectiveness of surveillance. We performed a systematic review and meta-analysis to identify factors associated with progression of BE without dysplasia or BE with low-grade dysplasia (LGD) to high-grade dysplasia or esophageal adenocarcinoma. METHODS: We performed a systematic search of databases through May 2016 to identify cohort studies of patients with baseline BE without dysplasia or BE with LGD that reported predictors of progression...
November 30, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29152554/prevalence-of-clostridium-difficile-infection-in-patients-after-radical-cystectomy-and-neoadjuvant-chemotherapy
#9
Katherine J Cotter, Yunhua Fan, Gretchen K Sieger, Christopher J Weight, Badrinath R Konety
Background and Objectives: Clostridium Difficile is the most common cause of nosocomial infectious diarrhea. This study evaluates the prevalence and predictors of Clostridium Difficile infections in patients undergoing radical cystectomy with or without neoadjuvant chemotherapy. Methods: Retrospective chart review was performed of all patients undergoing cystectomy and urinary diversion at a single institution from 2011-2017. Infection was documented in all cases with testing for Clostridium Difficile polymerase chain reaction toxin B...
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29134635/ribociclib-bioavailability-is-not-affected-by-gastric-ph-changes-or-food-intake-in-silico-and-clinical-evaluations
#10
Tanay S Samant, Shyeilla Dhuria, Yasong Lu, Marc Laisney, Shu Yang, Arnaud Grandeury, Martin Mueller-Zsigmondy, Kenichi Umehara, Felix Huth, Michelle Miller, Caroline Germa, Mohamed Elmeliegy
Ribociclib (KISQALI®), a cyclin-dependent kinase 4/6 inhibitor approved for the first-line treatment of HR+/HER2- advanced breast cancer with an aromatase inhibitor, is administered with no restrictions on concomitant gastric pH-elevating agents or food intake. The influence of proton pump inhibitors (PPIs) on ribociclib bioavailability was assessed using (1) biorelevant media solubility, (2) physiologically based pharmacokinetic (PBPK) modeling, (3) non-compartmental analysis (NCA) of clinical trial data, and (4) population PK (PopPK) analysis...
November 14, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29129090/screening-and-prevention-strategies-and-endoscopic-management-of-early-esophageal-cancer
#11
James A Kim, Pari M Shah
Esophageal cancer is the 8th most common cancer worldwide and the 6th most common cause of cancer-related death. Its two main subtypes, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), have varying incidences globally, but recent decades have seen a demonstrated rise of EAC in Western countries whereas ESCC remains highly prevalent in Eastern Africa, Central Asia, and China. Screening interventions have focused on using endoscopy to identify Barrett's esophagus (BE) as a precursor to EAC, and squamous cell dysplasia prior to onset of ESCC...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29122616/practice-patterns-of-medications-for-patients-with-malignant-bowel-obstruction-using-a-nationwide-claims-database-and-the-association-between-treatment-outcomes-and-concomitant-use-of-h2-blockers-proton-pump-inhibitors-and-corticosteroids-with-octreotide
#12
Takaaki Minoura, Masato Takeuchi, Tatsuya Morita, Koji Kawakami
CONTEXT: Malignant bowel obstruction (MBO) impairs the quality of life in patients with advanced cancer. Octreotide, acid-suppressing medications such as H<sub>(2)</sub>-receptor antagonists (H<sub>(2)</sub> blockers) and proton pump inhibitors (PPIs), and corticosteroids are often used in combination for symptom control. OBJECTIVES: We evaluated the practice patterns of medications for patients hospitalized with MBO using a large claims database in Japan...
November 6, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/29098281/factors-affecting-the-association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer
#13
Koen G A M Hussaarts, Roelof W F van Leeuwen, Ron H J Mathijssen
No abstract text is available yet for this article.
November 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29098276/factors-affecting-the-association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer
#14
Lishi Wang, Boern Shan, Weikuan Gu
No abstract text is available yet for this article.
November 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29098275/factors-affecting-the-association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer-reply
#15
Michael P Chu, Michael B Sawyer
No abstract text is available yet for this article.
November 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29098270/factors-affecting-the-association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer
#16
Guo-Fu Li, Guo Yu, Yan Gong
No abstract text is available yet for this article.
November 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29095917/comparison-of-the-human-gastric-microbiota-in-hypochlorhydric-states-arising-as-a-result-of-helicobacter-pylori-induced-atrophic-gastritis-autoimmune-atrophic-gastritis-and-proton-pump-inhibitor-use
#17
COMPARATIVE STUDY
Bryony N Parsons, Umer Z Ijaz, Rosalinda D'Amore, Michael D Burkitt, Richard Eccles, Luca Lenzi, Carrie A Duckworth, Andrew R Moore, Laszlo Tiszlavicz, Andrea Varro, Neil Hall, D Mark Pritchard
Several conditions associated with reduced gastric acid secretion confer an altered risk of developing a gastric malignancy. Helicobacter pylori-induced atrophic gastritis predisposes to gastric adenocarcinoma, autoimmune atrophic gastritis is a precursor of type I gastric neuroendocrine tumours, whereas proton pump inhibitor (PPI) use does not affect stomach cancer risk. We hypothesised that each of these conditions was associated with specific alterations in the gastric microbiota and that this influenced subsequent tumour risk...
November 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/29089382/long-term-proton-pump-inhibitors-and-risk-of-gastric-cancer-development-after-treatment-for-helicobacter-pylori-a-population-based-study
#18
MULTICENTER STUDY
Ka Shing Cheung, Esther W Chan, Angel Y S Wong, Lijia Chen, Ian C K Wong, Wai Keung Leung
OBJECTIVE: Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy. DESIGNS: This study was based on a territory-wide health database of Hong Kong. We identified adults who had received an outpatient prescription of clarithromycin-based triple therapy between year 2003 and 2012...
January 2018: Gut
https://www.readbyqxmd.com/read/29067276/characteristics-of-clostridium-difficile-infection-in-patients-hospitalized-with-myelodysplastic-syndrome-or-acute-myelogenous-leukemia
#19
Kamini Shah, Bryan F Curtin, Christopher Chu, Daniel Hwang, Mark H Flasar, Erik von Rosenvinge
AIM: To evaluate factors associated with Clostridium difficile infection (CDI) and outcomes of CDI in the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) population. METHODS: After IRB approval, all MDS/AML patients hospitalized at the University of Maryland Greenebaum Comprehensive Cancer Center between August 2011 and December 2013 were identified. Medical charts were reviewed for demographics, clinical information, development of CDI, complications of CDI, and mortality...
October 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29038303/f-actin-reorganization-by-v-atpase-inhibition-in-prostate-cancer
#20
Yamhilette Licon-Munoz, Vera Michel, Colleen A Fordyce, Karlett J Parra
The vacuolar ATPase (V-ATPase) proton pump sustains cellular pH homeostasis, and its inhibition triggers numerous stress responses. However, the cellular mechanisms involved remain largely elusive in cancer cells. We studied V-ATPase in the prostate cancer (PCa) cell line PC-3, which has characteristics of highly metastatic PCa. V-ATPase inhibitors impaired endo-lysosomal pH, vesicle trafficking, migration, and invasion. V-ATPase accrual in the Golgi and recycling endosomes suggests that traffic of internalized membrane vesicles back to the plasma membrane was particularly impaired...
November 15, 2017: Biology Open
keyword
keyword
114620
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"